Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs

AIDS Research and Human Retroviruses

Volumn 17, Issue 9, 2001, Pages 807-818

  Lukashov, V V ^a,b   Huismans, R ^b   Jebbink, M F ^a   Danner, S A ^a   De Boer, R J ^c   Goudsmit, J ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Amsterdam Institute of Viral Genomics   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIRETROVIRUS AGENT; NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; ZIDOVUDINE;

AMINO ACID SEQUENCE; ARTICLE; CASE REPORT; CONTROLLED STUDY; DISEASE MODEL; DRUG INTERMITTENT THERAPY; GENE INSERTION; GENETIC HETEROGENEITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOLECULAR CLONING; MOLECULAR EVOLUTION; MONOTHERAPY; MULTIDRUG RESISTANCE; PHYLOGENY; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SERUM; TIME; VIRUS GENE; VIRUS LOAD; VIRUS MUTANT; VIRUS MUTATION;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; BASE SEQUENCE; DNA, VIRAL; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; EVOLUTION, MOLECULAR; GENETIC HETEROGENEITY; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LAMIVUDINE; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; PHYLOGENY; REVERSE TRANSCRIPTASE INHIBITORS; SAQUINAVIR; STAVUDINE; TIME FACTORS; ZIDOVUDINE;

EID: 0034914629     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922201750252007     Document Type: Article

References (44)

1. Anti-retroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel
2. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS
3. Increasing survival time after AIDS in Italy: The role of new combination antiretroviral therapies
4. Estimating AIDS-free survival in a severely immunosuppressed asymptomatic HIV-infected population in the era of antiretroviral triple combination therapy. Swiss HIV Cohort Study
5. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy
6. HIV-1: Gambling on the evolution of drug resistance?
7. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management
8. Current knowledge of HIV-1 reverse transcriptase mutations selected during nucleoside analogue therapy: The potential to use resistance data to guide clinical decisions
9. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs
10. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors
11. Phenotypic and genotypic analysis of stuvudine (d4T) resistant isolates of HIV-1
12. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy
13. A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors
14. Emergence of HIV-1 variants containing codon insertions and deletions in the beta3-beta4 hairpin loop domain of reverse transcriptase
15. Different outcome in the first two patients with an HIV-1 multinucleoside drug-resistant T69SSS insertion in Spain
16. Dynamics of dominance of a dipeptide insertion in reverse transcriptase of HIV-1 from patients subjected to prolonged therapy
17. Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance
18. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues
19. Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1-infected Italian patients with virologic failure
20. Deletions in the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase are observed in HIV-1 isolated from subjects during long-term antiretroviral therapy
21. Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period
22. HIV-1 strains specific for Dutch injecting drug users in heterosexually infected individuals in The Netherlands
23. HIV heterogeneity and disease progression in AIDS: A model of continuous virus adaption
24. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
25. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span and viral generation time
26. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215
27. Estimating relative fitness in viral competition experiments
28. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment
29. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy
30. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance
31. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor
32. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy
33. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors
34. Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity
35. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro
36. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
37. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
38. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo
39. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus
40. Human immunodeficiency virus fitness in vivo: Calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase
41. Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera
42. Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates
43. Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy
44. Virus dynamics and drug therapy